University of Texas/Texas AM Investment Management Co (UTIMCO)’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30,488	Closed	-$428K	–	30
2017 Q2	$428K	Hold	30,488	–	–	1.27%	17
2017 Q1	$670K	Buy	+30,488	New	+$646K	1.75%	14

Other funds holding JNCE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s JNCE Position: Q3 2017 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2017, closing a stake of 30,488 shares — an estimated $428K sold.

University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in JNCE in Q1 2017 and held it in 2 quarters. The position peaked at $670K in Q1 2017. 76 funds tracked by Wall St. Rank hold JNCE as of Q3 2017.

University of Texas/Texas AM Investment Management Co (UTIMCO) reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
University of Texas/Texas AM Investment Management Co (UTIMCO) sold 30,488 Jounce Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $428K.
University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
University of Texas/Texas AM Investment Management Co (UTIMCO)'s Jounce Therapeutics, Inc. Common Stock position peaked at $670K in Q1 2017.
76 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2017.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q3 2017, filed 13 Nov 2017.